Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.
Nysom K, Kilburn LB, Leary SES, Landi DB, de Vos-Kerkhof E, Perreault S, Witt O, Ziegler DS, Hernáiz Driever P, Franson AT, Baxter PA, Whipple NS, Kline C, Segal D, Jabado N, Bailey S, McCowage G, Hansford JR, Khuong-Quang DA, Gottardo NG, Hassall T, Han JW, Yalon Oren M, Chi SN, Qiu J, Da Costa D, Govinda Raju S, Manley P, Hargrave D.
Nysom K, et al. Among authors: chi sn.
Neuro Oncol. 2024 Dec 19:noae274. doi: 10.1093/neuonc/noae274. Online ahead of print.
Neuro Oncol. 2024.
PMID: 39700439